HD-OPM Archive
Hashtags

#ezetimibereverse

11 posts

Six RCTs show statins reverse total plaque volume by 5% to 17%

Aug 25, 2026 · Louis Nervegna ♥ 27 · 💬 9 ↩ 1 Plaque, CAC & CT angiography

Louis lists six randomized trials showing reversal of total atheroma volume with statins: COSMOS ~5%, SATURN ~5.5%, ASTEROID ~6.5%, IBIS-4 ~7.5%, STABLE ~8%, JAPAN-ACS ~17%. Reversals were measured by CT angiography or IVUS and came from soft rather than calcified plaque. A shared chart relates LDL to TAV change across statin, PCSK9 and ezetimibe trials.

FLOWPROMOTE: LDL near 40 mg/dL on statin plus ezetimibe cut total plaque 21% in 18 months

Oct 31, 2026 · Louis Nervegna ♥ 25 · 💬 11 Plaque, CAC & CT angiography

Louis highlights the randomized FLOWPROMOTE trial in 104 statin-naive patients with coronary artery disease, scanned by CT angiography at baseline, 9 and 18 months. Rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL-C to 42.5 mg/dL versus 69.5 mg/dL with atorvastatin 40 mg and reduced total plaque volume by about 21%. The shared write-up frames this as evidence that coronary atherosclerosis can be reversed with intensive lipid lowering.

About 95% of acute-thrombosis heart attacks involve soft plaque, not calcified plaque

Oct 03, 2026 · Louis Nervegna ♥ 9 · 💬 9 Plaque, CAC & CT angiography

The post says about 64% of heart attacks from acute thrombosis come from rupture of soft lipid-rich plaque and about 25% from erosion of soft plaque, while only about 5% involve calcified nodules. Because statins and other lipid-lowering drugs stabilize and reverse soft plaque, the poster argues they address the plaque type most responsible for heart attacks.

FLOWPROMOTE: lower achieved LDL gave more plaque regression, 21.1% at LDL near 43

Oct 31, 2026 · Louis Nervegna ♥ 14 · 💬 4 Plaque, CAC & CT angiography

Louis adds FLOWPROMOTE to the pile of randomized trials showing statins reverse soft and total plaque. In 104 statin-naive stable CAD patients on CT angiography, LDL around 70 mg/dL gave a 13.6% total plaque reduction and around 43 mg/dL gave 21.1%, with 90% of the lower-LDL group showing regression. The linear LDL-to-regression relationship supports LDL being causal in atherosclerosis.

Six statin trials show 5 to 17% total plaque reversal, with the best results at lowest LDL

Oct 31, 2026 · Louis Nervegna ♥ 12 ↩ 1 Plaque, CAC & CT angiography

Louis shares a chart of randomized trials showing plaque reversal with statins, ezetimibe and PCSK9 inhibitors, with total atheroma volume change plotted against LDL-C. Total plaque reversal ranged from about 5% to 17% in six older statin trials, measured by CT angiography or IVUS, and came from soft rather than calcified plaque. The chart suggests total plaque reversal begins once LDL falls below roughly 90 mg/dL.

A rising calcium score on a statin does not mean it failed, per FLOWPROMOTE details

Nov 08, 2026 · Louis Nervegna ♥ 1 Plaque, CAC & CT angiography

Louis shares a cardiologist's explanation that a higher calcium score on a statin neither proves failure nor success, since plaque picks up calcium as it hardens and denser calcium counts extra. It summarizes FLOWPROMOTE: atorvastatin 40 mg vs rosuvastatin 40 mg plus ezetimibe 10 mg lowered LDL more and shrank total plaque more in 18 months while calcified plaque grew in both groups. These were secondary results of a small trial on CT, not event outcomes.